Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-human, Randomized, Participant- and Investigator-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ETH47 in Healthy Participants

NCT07055321 is registered in ClinicalTrials.gov with Ethris GmbH as lead sponsor.

NCT NCT07055321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07055321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-human, Randomized, Participant- and Investigator-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of ETH47 in Healthy Participants
Lead sponsor
Ethris GmbH
Phase
Phase 1
Overall status
Completed
Start date
November 29, 2023
Completion date
July 8, 2024
Enrollment
73 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subjects